Clinical Trials Browser

Active not recruiting × trastuzumab deruxtecan × 30 days × Clear all

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 1 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04622319 2026-05-15

DESTINY-Breast05

Phase 3 Active not recruiting

1,600 enrolled 1 FDA

HER2-Positive Primary Breast Cancer

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1 Active not recruiting

BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06663787 2026-05-13

HER2 CR

Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT04739761 2026-05-12

DESTINY-B12

Phase 3 Active not recruiting

506 enrolled 27 charts

Brain Neoplasms, Breast Neoplasms

NCT05246514 2026-05-12

DL-05

Phase 2 Active not recruiting

72 enrolled 19 charts

HER2-mutant Non-Small Cell Lung Cancer

NCT06271837 2026-05-11

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Active not recruiting

Breast Neoplasms

NCT06048718 2026-05-08

TUXEDO-4

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms